The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
|ClinicalTrials.gov Identifier: NCT01843881|
Recruitment Status : Completed
First Posted : May 1, 2013
Last Update Posted : December 4, 2013
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Mellitus||Drug: Exendin 9, 39 Drug: Placebo||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||September 2013|
|Actual Study Completion Date :||December 2013|
Experimental: Exendin 9, 39
Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
Drug: Exendin 9, 39
Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
Placebo Comparator: Placebo
A saline infusion will be administered in either first intervention period or second intervention period.
A saline infusion will be given to match the study drug infusion.
- Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline) [ Time Frame: Day 1, Day 2 (approximately 2 weeks after day 1) ]The total disposition index equals the product of insulin secretion and insulin sensitivity.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01843881
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Adrian Vella, M.D.||Mayo Clinic|